Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,081 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pseudoexfoliative Deposits on an Intraocular Lens.
Bhattacharjee H, Mishra S, Garg M. Bhattacharjee H, et al. Among authors: mishra s. JAMA Ophthalmol. 2023 Jun 1;141(6):e230407. doi: 10.1001/jamaophthalmol.2023.0407. Epub 2023 Jun 15. JAMA Ophthalmol. 2023. PMID: 37318530
Bilateral sub-internal limiting membrane hemorrhage in a COVID-19 patient.
Ghodake A, Das D, Bhattacharjee H, Barman MJ, Magdalene D, Ghosh R, Mishra S. Ghodake A, et al. Among authors: mishra s. Indian J Ophthalmol. 2022 Aug;70(8):3141-3142. doi: 10.4103/ijo.IJO_337_22. Indian J Ophthalmol. 2022. PMID: 35918991 Free PMC article. No abstract available.
Differential Burden of HIV Among Adolescent Girls and Young Women by Places Associated With Sex Work: An Observational Study in Mombasa, Kenya.
Becker M, Mishra S, Bhattacharjee P, Musyoki H, Tennakoon A, Leung S, Cheuk E, Lorway R, Isac S, Ma H, Cholette F, Sandstrom P, Gichangi P, Mwatelah R, Mckinnon L, Blanchard J, Pickles M; Transitions Study Team. Becker M, et al. Among authors: mishra s. J Acquir Immune Defic Syndr. 2024 Jun 1;96(2):121-129. doi: 10.1097/QAI.0000000000003412. J Acquir Immune Defic Syndr. 2024. PMID: 38771751
Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
Coutts SB, Ankolekar S, Appireddy R, Arenillas JF, Assis Z, Bailey P, Barber PA, Bazan R, Buck BH, Butcher KS, Camden MC, Campbell B, Casaubon LK, Catanese L, Chatterjee K, Choi PMC, Clarke B, Dowlatshahi D, Ferrari J, Field TS, Ganesh A, Ghia D, Goyal M, Greisenegger S, Halse O, Horn M, Hunter G, Imoukhuede O, Kelly PJ, Kennedy J, Kenney C, Kleinig TJ, Krishnan K, Lima F, Mandzia JL, Marko M, Martins SO, Medvedev G, Menon BK, Mishra SM, Molina C, Moussaddy A, Muir KW, Parsons MW, Penn AMW, Pille A, Pontes-Neto OM, Roffe C, Serena J, Simister R, Singh N, Spratt N, Strbian D, Tham CH, Wiggam MI, Williams DJ, Willmot MR, Wu T, Yu AYX, Zachariah G, Zafar A, Zerna C, Hill MD; TEMPO-2 investigators. Coutts SB, et al. Among authors: mishra sm. Lancet. 2024 May 16:S0140-6736(24)00921-8. doi: 10.1016/S0140-6736(24)00921-8. Online ahead of print. Lancet. 2024. PMID: 38768626
7,081 results